4D Molecular Therapeutics, Inc. Increase Decrease In Operating Lease Liability
4D Molecular Therapeutics, Inc. (FDMT) reported Increase Decrease In Operating Lease Liability of -$1.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$905.00K.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$878.00K.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$850.00K.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$814.00K.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$3.19M.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.65M.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.45M.
- 4D Molecular Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$324.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$905.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.78M 10-Q · filed 2026-08-13 | -$2.63M derived: sum of 3 quarters · filed 2026-08-13 | -$3.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$878.00K 10-Q · filed 2026-05-07 | -$1.73M derived: sum of 2 quarters · filed 2026-05-07 | -$2.54M derived: sum of 3 quarters · filed 2026-05-07 | -$3.32M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$850.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$1.66M derived: sum of 2 quarters · filed 2026-03-18 | -$2.44M derived: sum of 3 quarters · filed 2026-08-13 | -$3.19M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.59M derived: sum of 2 quarters · filed 2026-08-13 | -$2.34M 10-Q · filed 2025-11-10 | -$2.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$775.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.53M 10-Q · filed 2026-08-13 | -$1.76M derived: sum of 3 quarters · filed 2026-08-13 | -$2.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$754.00K 10-Q · filed 2026-05-07 | -$981.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.39M derived: sum of 3 quarters · filed 2026-05-07 | -$1.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$635.00K derived: sum of 2 quarters · filed 2026-03-18 | -$1.15M derived: sum of 3 quarters · filed 2026-03-18 | -$1.65M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$923.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.42M 10-Q · filed 2025-11-10 | -$1.91M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$515.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.02M 10-Q · filed 2025-08-11 | -$1.50M derived: sum of 3 quarters · filed 2025-08-11 | -$1.98M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$501.00K 10-Q · filed 2025-05-08 | -$987.00K derived: sum of 2 quarters · filed 2025-05-08 | -$1.46M derived: sum of 3 quarters · filed 2025-05-08 | -$1.51M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$486.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$959.00K derived: sum of 2 quarters · filed 2025-02-28 | -$1.01M derived: sum of 3 quarters · filed 2025-02-28 | -$1.45M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$473.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$524.00K derived: sum of 2 quarters · filed 2024-11-13 | -$967.00K 10-Q · filed 2024-11-13 | -$1.40M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$494.00K 10-Q · filed 2024-08-08 | -$922.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$443.00K 10-Q · filed 2024-05-09 | -$871.00K derived: sum of 2 quarters · filed 2024-05-09 | -$1.32M derived: sum of 3 quarters · filed 2024-05-09 | -$1.14M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$874.00K derived: sum of 2 quarters · filed 2024-02-29 | -$695.00K derived: sum of 3 quarters · filed 2024-02-29 | -$324.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$446.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$267.00K derived: sum of 2 quarters · filed 2023-11-09 | $104.00K 10-Q · filed 2023-11-09 | $221.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $550.00K 10-Q · filed 2023-08-09 | $667.00K derived: sum of 3 quarters · filed 2023-08-09 | $287.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $371.00K 10-Q · filed 2023-05-11 | $488.00K derived: sum of 2 quarters · filed 2023-05-11 | $108.00K derived: sum of 3 quarters · filed 2023-05-11 | -$264.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$263.00K derived: sum of 2 quarters · filed 2023-03-15 | -$635.00K derived: sum of 3 quarters · filed 2023-03-15 | -$1.00M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$380.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$752.00K derived: sum of 2 quarters · filed 2022-11-08 | -$1.12M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$737.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$365.00K 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |